Endoradiotherapy in cancer treatment - Basic concepts and future trends

European Journal of Pharmacology

Volumn 625, Issue 1-3, 2009, Pages 55-62

  Zoller, Frederic ^a,b   Eisenhut, Michael ^a   Haberkorn, Uwe ^a,b   Mier, Walter ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Bifunctional chelators; Endoradiotherapy; Peptide receptor radiation therapy; Peptide scaffolds; Radioimmunotherapy

Indexed keywords

ACTINIUM 225; ASTATINE 211; ASTATO METHYLNAPHTHOQUINOL DIPHOSPHATE AT 211; BISMUTH 213; CITRATE ER 169; COPPER 67; ERBIUM 169; IBRITUMOMAB TIUXETAN; IDOXURIDINE I 125; INDIUM 111; IODINE 125; IODINE 131; LUTETIUM 177; META JODOBENZYLGUANIDINE I 131; MONOCLONAL ANTIBODY B.72.3 I 131; MONOCLONAL ANTIBODY CC49 I 131; MONOCLONAL ANTIBODY CC49 LU 177; MONOCLONAL ANTIBODY CHL6 I 131; MONOCLONAL ANTIBODY HMFG 1 Y 90; MONOCLONAL ANTIBODY NP 4 I 131; MONOCLONAL ANTIBODY R1549 Y 90; PENTETREOTIDE; PENTETREOTIDE IN 111; PHOSPHORUS 32; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; SULFATE RE 186; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 90; YTTRIUM CITRATE Y 90;

BLOOD TOXICITY; CANCER RADIOTHERAPY; DRUG HALF LIFE; HUMAN; HYPERTHYROIDISM; IONIZING RADIATION; ISOTOPE LABELING; LINEAR ENERGY TRANSFER; PRIORITY JOURNAL; RADIOBIOLOGY; RADIOIMMUNOTHERAPY; REVIEW; THYROID CANCER;

ANIMALS; ANTIBODIES; BINDING SITES; HUMANS; NEOPLASMS; PEPTIDES; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RECEPTORS, PEPTIDE;

EID: 71749098171     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.05.035     Document Type: Review

References (95)

1. Adam M.J., and Wilbur D.S. Radiohalogens for imaging and therapy. Chemical Society Reviews 34 (2005) 153-163
2. Anderson C.J., John C.S., Li Y.J., Hancock R.D., McCarthy T.J., Martell A.E., and Welch M.J. N, N′-ethylene-di-l-cysteine (EC) complexes of Ga(III) and In(III): molecular modeling, thermodynamic stability and in vivo studies. Nuclear Medicine and Biology 22 (1995) 165-173
3. Askoxylakis V., Zitzmann S., Mier W., Graham K., Kramer S., von Wegner F., Fink R.H., Schwab M., Eisenhut M., and Haberkorn U. Preclinical evaluation of the breast cancer cell-binding peptide, p160. Clinical Cancer Research 11 (2005) 6705-6712
4. Askoxylakis V., Mier W., Zitzmann S., Ehemann V., Zhang J., Kramer S., Beck C., Schwab M., Eisenhut M., and Haberkorn U. Characterization and development of a peptide (p160) with affinity for neuroblastoma cells. Journal of Nuclear Medicine 47 (2006) 981-988
5. Bakker W.H., Krenning E.P., Reubi J.C., Breeman W.A., Setyono-Han B., de Jong M., Kooij P.P., Bruns C., van Hagen P.M., Marbach P., et al. In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sciences 49 (1991) 1593-1601
6. Behr T.M., Sharkey R.M., Juweid M.E., Dunn R.M., Vagg R.C., Ying Z., Zhang C.H., Swayne L.C., Vardi Y., Siegel J.A., and Goldenberg D.M. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. Journal of Nuclear Medicine 38 (1997) 858-870
7. Bloomer W.D., and Adelstein S.J. 5-125I-iododeoxyuridine as prototype for radionuclide therapy with Auger emitters. Nature 265 (1977) 620-621
8. Brans B., Monsieurs M., Laureys G., Kaufman J.M., Thierens H., and Dierckx R.A. Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking. Medical and Pediatric Oncology 38 (2002) 41-46
9. Brechbiel M.W. Bifunctional Chelates for Metal Nuclides. Quarterly Journal of Nuclear Medicine and Molecular Imaging 52 (2008) 166-173
10. Brown I., and Mitchell J.S. The development of a [211At]-astatinated endoradiotherapeutic drug: part IV - late radiation effects. International Journal of Radiation Oncology, Biology, Physics 40 (1998) 1177-1183
11. Camera L., Kinuya S., Garmestani K., Wu C., Brechbiel M.W., Pai L.H., McMurry T.J., Gansow O.A., Pastan I., Paik C.H., et al. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. Journal of Nuclear Medicine 35 (1994) 882-889
12. Chang C.H., Sharkey R.M., Rossi E.A., Karacay H., McBride W., Hansen H.J., Chatal J.F., Barbet J., and Goldenberg D.M. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Molecular Cancer Therapeutics 1 (2002) 553-563
13. Clark R.J., Daly N.L., and Craik D.J. Structural plasticity of the cyclic-cystine-knot framework: implications for biological activity and drug design. Biochemical Journal 394 (2006) 85-93
14. Craik D.J., Cemazar M., and Daly N.L. The cyclotides and related macrocyclic peptides as scaffolds in drug design. Current Opinion in Drug Discovery & Development 9 (2006) 251-260
15. Craik D.J., Cemazar M., and Daly N.L. The chemistry and biology of cyclotides. Current Opinion in Drug Discovery & Development 10 (2007) 176-184
16. de Jong M., Breeman W.A., Valkema R., Bernard B.F., and Krenning E.P. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. Journal of Nuclear Medicine 46 Suppl 1 (2005) 13S-17S
17. Denardo S.J., O'Grady L.F., Richman C.M., Goldstein D.S., O'Donnell R.T., Denardo D.A., Kroger L.A., Lamborn K.R., Hellstrom K.E., Hellstrom I., and Denardo G.L. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Research 17 (1997) 1745-1751
18. Diller D.J. The synergy between combinatorial chemistry and high-throughput screening. Current Opinion in Drug Discovery & Development 11 (2008) 346-355
19. DuBois S.G., and Matthay K.K. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nuclear Medicine and Biology 35 Suppl 1 (2008) S35-S48
20. Erwin W.D., Spies S.M., Kelly M.E., Rao P., Eckersberg-Rhodes T.E., Nannapaneni M., and Groch M.W. Correlation of marrow dose estimates based on serial pretreatment radiopharmaceutical imaging and blood data with actual marrow toxicity in anti-CD20 yttrium-90 monoclonal antibody radioimmunotherapy of non-Hodgkin's B-cell lymphoma. Nuclear Medicine Communications 22 (2001) 247-255
21. Esteban J.M., Felder B., Ahn C., Simpson J.F., Battifora H., and Shively J.E. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients. Cancer 74 (1994) 1575-1583
22. Fortin M.A., Orlova A., Malmstrom P.U., and Tolmachev V. Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. International Journal of Molecular Medicine 19 (2007) 285-291
23. Garcia Boy R., Haberkorn U., and Mier W. Stabilisation of small proteins for their use as pharmacological scaffolds - why knot?. Chimica Oggi-Chemistry Today 25 (2007) 37-39
24. Goldenberg D.M., Sharkey R.M., Paganelli G., Barbet J., and Chatal J.F. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. Journal of Clinical Oncology 24 (2006) 823-834
25. Gong M.C., Chang S.S., Sadelain M., Bander N.H., and Heston W.D. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metastasis Reviews 18 (1999) 483-490
26. Gotthardt M., Boermann O.C., Behr T.M., Behe M.P., and Oyen W.J. Development and clinical application of peptide-based radiopharmaceuticals. Current Pharmaceutical Design 10 (2004) 2951-2963
27. Graham K., Wang Q., Garcia Boy R., Eisenhut M., Haberkorn U., and Mier W. Synthesis and evaluation of intercalating somatostatin receptor binding peptide conjugates for endoradiotherapy. Journal of Pharmacy & Pharmaceutical Sciences 10 (2007) 286s-297s
28. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. Journal of Drug Targeting 15 (2007) 457-464
29. Griggs W.S., and Divgi C. Radioiodine imaging and treatment in thyroid disorders. Neuroimaging Clinics of North America 18 (2008) 505-515 viii
30. Haberer T., Debus J., Eickhoff H., Jakel O., Schulz-Ertner D., and Weber U. The Heidelberg Ion Therapy Center. Radiotherapy & Oncology 73 Suppl 2 (2004) S186-S190
31. Haberkorn U., and Eisenhut M. Molecular imaging and therapy - a programme based on the development of new biomolecules. European Journal of Nuclear Medicine and Molecular Imaging 32 (2005) 1354-1359
32. Haberkorn U., Eisenhut M., Altmann A., and Mier W. Endoradiotherapy with peptides - status and future development. Current Medicinal Chemistry 15 (2008) 219-234
33. Hajjar G., Sharkey R.M., Burton J., Zhang C.H., Yeldell D., Matthies A., Alavi A., Losman M.J., Brenner A., and Goldenberg D.M. Phase I radioimmunotherapy trial with iodine-131-labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clinical Colorectal Cancer 2 (2002) 31-42
34. Hnatowich D.J., Virzi F., and Rusckowski M. Investigations of avidin and biotin for imaging applications. Journal of Nuclear Medicine 28 (1987) 1294-1302
35. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., and Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proceedings of the National Academy of Sciences of the United States of America 95 (1998) 4607-4612
36. ICRU. Stopping Powers for Electrons and Positions (Report 37) (1984)
37. ICRU. Stopping Powers and Range for Protons and Alpha Particels (Report 49) (1993)
38. Jain R.K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Research 50 (1990) 814s-819s
39. Jakel O., Karger C.P., and Debus J. The future of heavy ion radiotherapy. Medical Physics 35 (2008) 5653-5663
40. Jansson B., Uhlen M., and Nygren P.A. All individual domains of staphylococcal protein A show Fab binding. FEMS Immunology and Medical Microbiology 20 (1998) 69-78
41. Kaltsas G.A., Papadogias D., Makras P., and Grossman A.B. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocrine-Related Cancer 12 (2005) 683-699
42. Kaminski M.S., Zelenetz A.D., Press O.W., Saleh M., Leonard J., Fehrenbacher L., Lister T.A., Stagg R.J., Tidmarsh G.F., Kroll S., Wahl R.L., Knox S.J., and Vose J.M. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. Journal of Clinical Oncology 19 (2001) 3918-3928
43. Kassis A.I. Therapeutic radionuclides: biophysical and radiobiologic principles. Seminars in Nuclear Medicine 38 (2008) 358-366
44. Kassis A.I., and Adelstein S.J. Radiobiologic principles in radionuclide therapy. Journal of Nuclear Medicine 46 Suppl 1 (2005) 4S-12S
45. Khodjibekova M., Szyszko T., Khan S., Nijran K., Tait P., and Al-Nahhas A. Selective internal radiation therapy with Yttrium-90 for unresectable liver tumours. Reviews on Recent Clinical Trials 2 (2007) 212-216
46. Kocher D. Radioactive Decay Data Table: A Handbook of Decay Data for Application to Radiation Dosimetry and Radiological Assessments (1981), National Technical Information Center, US Department of Energy, Springfield, Virgina
47. Kotts C.E., Su F.M., Leddy C., Dodd T., Scates S., Shalaby M.R., Wirth C.M., Giltinan D., Schroff R.W., Fritzberg A.R., Shepard H.M., Slamon D.J., and Hutchins B.M. 186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterparts. Cancer Biotherapy & Radiopharmaceuticals 11 (1996) 133-144
48. Kwekkeboom D.J., Mueller-Brand J., Paganelli G., Anthony L.B., Pauwels S., Kvols L.K., O'Dorisio T.M., Valkema R., Bodei L., Chinol M., Maecke H.R., and Krenning E.P. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. Journal of Nuclear Medicine 46 Suppl 1 (2005) 62S-66S
49. Lendel C., Dogan J., and Hard T. Structural Basis for Molecular Recognition in an Affibody: Affibody Complex RCSB Protein Database (2006)
50. Liu S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Advanced Drug Delivery Reviews 60 (2008) 1347-1370
51. Marasco D., Perretta G., Sabatella M., and Ruvo M. Past and future perspectives of synthetic peptide libraries. Current Protein & Peptide Science 9 (2008) 447-467
52. Martin L., and Vita C. Engineering novel bioactive mini-proteins from small size natural and de novo designed scaffolds. Current Protein & Peptide Science 1 (2000) 403-430
53. McDevitt M.R., Sgouros G., Finn R.D., Humm J.L., Jurcic J.G., Larson S.M., and Scheinberg D.A. Radioimmunotherapy with alpha-emitting nuclides. European Journal of Nuclear Medicine 25 (1998) 1341-1351
54. Meredith R.F., Khazaeli M.B., Macey D.J., Grizzle W.E., Mayo M., Schlom J., Russell C.D., and LoBuglio A.F. Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clinical Cancer Research 5 (1999) 3254s-3258s
55. Nilsson B., Moks T., Jansson B., Abrahmsen L., Elmblad A., Holmgren E., Henrichson C., Jones T.A., and Uhlen M. A synthetic IgG-binding domain based on staphylococcal protein A. Protein Engineering 1 (1987) 107-113
56. Nord K., Nilsson J., Nilsson B., Uhlen M., and Nygren P.A. A combinatorial library of an alpha-helical bacterial receptor domain. Protein Engineering 8 (1995) 601-608
57. Nord K., Gunneriusson E., Ringdahl J., Stahl S., Uhlen M., and Nygren P.A. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nature Biotechnology 15 (1997) 772-777
58. Nygren P.A. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS Journal 275 (2008) 2668-2676
59. Nygren P.A., and Skerra A. Binding proteins from alternative scaffolds. Journal of Immunological Methods 290 (2004) 3-28
60. O'Donnell R.T., DeNardo S.J., Yuan A., Shen S., Richman C.M., Lara P.N., Griffith I.J., Goldstein D.S., Kukis D.L., Martinez G.S., Mirick G.R., DeNardo G.L., and Meyers F.J. Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer. Clinical Cancer Research 7 (2001) 1561-1568
61. Oriuchi N., Higuchi T., Hanaoka H., Iida Y., and Endo K. Current status of cancer therapy with radiolabeled monoclonal antibody. Annals of Nuclear Medicine 19 (2005) 355-365
62. Orlova A., Magnusson M., Eriksson T.L., Nilsson M., Larsson B., Hoiden-Guthenberg I., Widstrom C., Carlsson J., Tolmachev V., Stahl S., and Nilsson F.Y. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Research 66 (2006) 4339-4348
63. Oyen W.J., Bodei L., Giammarile F., Maecke H.R., Tennvall J., Luster M., and Brans B. Targeted therapy in nuclear medicine-current status and future prospects. Annals of Oncology 18 (2007) 1782-1792
64. Pagel J.M., Matthews D.C., Kenoyer A., Hamlin D.K., Wilbur D.S., Fisher D.R., Gopal A.K., Lin Y., Saganic L., Appelbaum F.R., and Press O.W. Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia. Cancer Research 69 (2009) 185-192
65. Price T.J., and Townsend A. Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastases. Archives of Surgery 143 (2008) 313-314
66. Reardan D.T., Meares C.F., Goodwin D.A., McTigue M., David G.S., Stone M.R., Leung J.P., Bartholomew R.M., and Frincke J.M. Antibodies against metal chelates. Nature 316 (1985) 265-268
67. Sautter-Bihl M.L., Herbold G., and Bihl H. Minimal residual disease: a target for radioimmunotherapy with 131I-labeled monoclonal antibodies? Some dosimetric considerations. Recent results in cancer research. Fortschritte der Krebsforschung 141 (1996) 67-75
68. Schlom J., Siler K., Milenic D.E., Eggensperger D., Colcher D., Miller L.S., Houchens D., Cheng R., Kaplan D., and Goeckeler W. Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate. Cancer Research 51 (1991) 2889-2896
69. Schneider P., Farahati J., and Reiners C. Radiosynovectomy in rheumatology, orthopedics, and hemophilia. Journal of Nuclear Medicine 46 Suppl 1 (2005) 48S-54S
70. Schrier D.M., Stemmer S.M., Johnson T., Kasliwal R., Lear J., Matthes S., Taffs S., Dufton C., Glenn S.D., Butchko G., et al. High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial. Cancer Research 55 (1995) 5921s-5924s
71. Seifert S., Kunstler J.U., Schiller E., Pietzsch H.J., Pawelke B., Bergmann R., and Spies H. Novel procedures for preparing 99mTc(III) complexes with tetradentate/monodentate coordination of varying lipophilicity and adaptation to 188Re analogues. Bioconjugate Chemistry 15 (2004) 856-863
72. Sharkey R.M., and Goldenberg D.M. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. Journal of Nuclear Medicine 46 Suppl 1 (2005) 115S-127S
73. Sharkey R.M., and Goldenberg D.M. Advances in radioimmunotherapy in the age of molecular engineering and pretargeting. Cancer Investigation 24 (2006) 82-97
74. Sharkey R.M., Karacay H., Litwin S., Rossi E.A., McBride W.J., Chang C.H., and Goldenberg D.M. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Research 68 (2008) 5282-5290
75. Skjeldal L., Gran L., Sletten K., and Volkman B.F. Refined Structure and Disulfide Paaring of the Kalata B1 Peptide RCSB Protein Database (2002)
76. Smith G.P., and Petrenko V.A. Phage display. Chemical Reviews 97 (1997) 391-410
77. Snyder A.R. Review of radiation-induced bystander effects. Human & Experimental Toxicology 23 (2004) 87-89
78. Sofou S. Radionuclide carriers for targeting of cancer. International Journal of Nanomedicine 3 (2008) 181-199
79. Tennvall J., and Brans B. EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases. European Journal of Nuclear Medicine and Molecular Imaging 34 (2007) 1324-1327
80. Tolmachev V., Orlova A., Nilsson F.Y., Feldwisch J., Wennborg A., and Abrahmsen L. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opinion on Biological Therapy 7 (2007) 555-568
81. Tolmachev V., Orlova A., Pehrson R., Galli J., Baastrup B., Andersson K., Sandstrom M., Rosik D., Carlsson J., Lundqvist H., Wennborg A., and Nilsson F.Y. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Research 67 (2007) 2773-2782
82. Van Essen M., Krenning E.P., De Jong M., Valkema R., and Kwekkeboom D.J. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncologica 46 (2007) 723-734 (Stockholm, Sweden)
83. Verheijen R.H., Massuger L.F., Benigno B.B., Epenetos A.A., Lopes A., Soper J.T., Markowska J., Vyzula R., Jobling T., Stamp G., Spiegel G., Thurston D., Falke T., Lambert J., and Seiden M.V. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. Journal of Clinical Oncology 24 (2006) 571-578
84. Vorherr T. Peptides as drugs - molecular evolvement in recent years. Pharmaceutical Chemistry (2008) 13-16
85. Wangler C., Buchmann I., Eisenhut M., Haberkorn U., and Mier W. Radiolabeled peptides and proteins in cancer therapy. Protein & Peptide Letters 14 (2007) 273-279
86. Ward J.F. Mechanisms of DNA repair and their potential modification for radiotherapy. International Journal of Radiation Oncology, Biology, Physics 12 (1986) 1027-1032
87. Weiner R.E., and Thakur M.L. Radiolabeled peptides in oncology - role in diagnosis and treatment. BioDrugs 19 (2005) 145-163
88. Wessels B.W., and Rogus R.D. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Medical Physics 11 (1984) 638-645
89. Wikman M., Steffen A.C., Gunneriusson E., Tolmachev V., Adams G.P., Carlsson J., and Stahl S. Selection and characterization of HER2/neu-binding affibody ligands. Protein Engineering, Design and Selection 17 (2004) 455-462
90. Witzig T.E., Gordon L.I., Cabanillas F., Czuczman M.S., Emmanouilides C., Joyce R., Pohlman B.L., Bartlett N.L., Wiseman G.A., Padre N., Grillo-Lopez A.J., Multani P., and White C.A. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology 20 (2002) 2453-2463
91. Wong J.Y., Shibata S., Williams L.E., Kwok C.S., Liu A., Chu D.Z., Yamauchi D.M., Wilczynski S., Ikle D.N., Wu A.M., Yazaki P.J., Shively J.E., Doroshow J.H., and Raubitschek A.A. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clinical Cancer Research 9 (2003) 5842-5852
92. Wu A.M., and Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nature Biotechnology 23 (2005) 1137-1146
93. Zheng Y.Y., Saluja S., Yap G.P., Blumenstein M., Rheingold A.L., and Francesconi L.C. Gallium and indium complexes of bis(amino thiol) (N(2)S(2)) ligands. Inorganic Chemistry 35 (1996) 6656-6666
94. Zitzmann S., Kramer S., Mier W., Mahmut M., Fleig J., Altmann A., Eisenhut M., and Haberkorn U. Identification of a new prostate-specific cyclic peptide with the bacterial FliTrx system. Journal of Nuclear Medicine 46 (2005) 782-785
95. Zitzmann S., Kramer S., Mier W., Hebling U., Altmann A., Rother A., Berndorff D., Eisenhut M., and Haberkorn U. Identification and evaluation of a new tumor cell-binding peptide, FROP-1. Journal of Nuclear Medicine 48 (2007) 965-972